117 / 150
Radiofármacos en el manejo del dolor óseo metastásico
>
117
Montebello JF, Hartson-Eaton M. The palliation of osseous metastasis with 32P or 89Sr compared with external
beam and hemibody irradiation: a historical perspective. Cancer Invest. 1989;7:139-60.
Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alphaemitting radium-223 in the treatment of
skeletal metastases. Clin Cancer Res. 2005;11:4451-9.
Oosterhof GO, Roberts JT, de Reijke TM, et al. Strontium(89) chloride versus palliative local field radiotherapy in
patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and
Treatment of Cancer Genitourinary Group. Eur Urol. 2003;44:519-26.
Palmedo H, Manka-Waluch A, Albers P, et al. Repeated bone-targeted therapy for hormone-refractory prostate car-
cinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidene
diphosphonate. J Clin Oncol. 2003;21:2869-75.
Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of stron-
tium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic
prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805-13.
Sciuto R, Festa A, Pasqualoni R, et al. Metastatic bone pain palliation with 89Sr and 186Re-HEDP in breast cancer
patients. Breast Cancer Res Treat. 2001;66:101-9.
Sciuto R, Festa A, Rea S, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from pros-
tate cancer: a randomized clinical trial. J Nucl Med. 2002;43:79-86.
Smeland S, Erikstein B, Aas M, et al. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is
questionable: results of a double blind randomized study. Int J Radiat Oncol Biol Phys. 2003;56:1397-404.
Storto G, Klain M, Paone G, et al. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone
metastases. Bone. 2006;39:35-41.
Van der Poel HG, Antonini N, Hoefnagel CA, et al. Serum hemoglobin levels predict response to strontium-89 and
rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer. Urol Int. 2006;77:50-6.
Widmark A, Modig H, Johansson M, et al. TAXSAM: a new chemo-radiation regimen for bone metastases in hor-
mone refractory prostate cancer. Proceedings Prostate Cancer Symposium. 2006;1:204.
Windsor PM. Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report
of a single centre’s 10-year experience. Clin Oncol (R Coll Radiol). 2001;13:219-27.